Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ThisCART19A in refractory or relapsed B-cell lymphoma
NCT05776407Phase 2Unknown
- Sponsor
- Chongqing University Cancer Hospital
- Start
- May 2023
- Primary completion
- May 2024
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label trial of thiscart19a in B cell lymphoma, sponsored by Chongqing University Cancer Hospital. Status: unknown.
02
Drugs
thiscart19a
03
Conditions
B cell lymphoma
Beyond the preview
Go deeper on NCT05776407.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05776407.